非小细胞肺癌患者抗PD-L1治疗前后NK细胞动态变化与治疗反应性的相关性-东南大学学报医学版

非小细胞肺癌患者抗PD-L1治疗前后NK细胞动态变化与治疗反应性的相关性

单位：河北省邯郸市中心医院肿瘤三科, 河北邯郸 056000

分类号：R734.2

出版年·卷·期（页码）：2023·42·第五期（666-672）

摘要：

目的:探讨非小细胞肺癌(NSCLC)患者抗程序性死亡配体-1(PD-L1)治疗前后自然杀伤(NK)细胞动态变化与治疗反应性的相关性。方法:选择2020年3月至2021年12月于我院确诊的NSCLC患者100例,所有患者分期均为Ⅲ期及以上,不能进行手术切除。在开始抗PD-L1治疗前收集患者资料,并在治疗前及治疗1个疗程时抽取患者静脉血行流式细胞术,对患者两个时间点的辅助T(Th)细胞、细胞毒性T(Tc)细胞、B细胞及NK细胞分化情况进行分析。根据患者治疗反应性将患者分为疾病控制(DC)组和疾病进展(PD)组,采用Logistic回归分析影响治疗反应性的相关因素。结果:最终纳入研究的患者共93例,DC 组67例,PD组26例。DC组患者治疗后中性粒细胞与淋巴细胞比值(NLR)低于PD组,而治疗后NK细胞高于PD组(P<0.05);DC组患者治疗前后NK细胞差值及治疗前后比值均明显低于PD组(U=-1.963、-2.005,P=0.049、0.045)。治疗后NLR、NK治疗前后比值、PD-L1是影响NSCLC患者免疫治疗效果的独立因素(P<0.05)。随着NK细胞治疗前后比值升高,NSCLC患者治疗反应为PD的风险呈升高趋势(非线性=0.376,P=0.099)。结论:NSCLC患者抗PD-L1治疗前后NK细胞动态变化与治疗反应性具有显著相关性。

Objective: To investigate the relationship between the dynamic changes of natural killer(NK) cells and therapeutic responsiveness in patients with non-small cell lung cancer(NSCLC) before and after anti programmed death ligand 1(PD-L1)therapy. Methods: 100 patients with NSCLC diagnosed in our hospital from March 2020 to December 2021 were selected. All patients were in stage Ⅲ or above and could not be resected surgically. The clinical data of patients were collected before the start of anti PD-L1 treatment, and the venous blood of patients was drawn before treatment and during one course of treatment for flow cytometry to analyze the differentiation of helper T(Th) cells, cytotoxic T(Tc) cells, B cells and NK cells at two time points. Patients were divided into disease control(DC) group and disease progression(PD) group according to their response to treatment, and then the related factors affecting the treatment response were analyzed by Logistic regression. Results: A total of 93 patients finally included in the study, 67 cases in DC group and 26 cases in PD group. After treatment, the ratio of neutrophils to lymphocytes(NLR) in DC group was lower than that in PD group, while the NK cells in DC group were higher than that in PD group(P<0.05). The difference and ratio of NK cells before and after treatment in DC group were significantly lower than those in PD group(U=-1.963, -2.005; P=0.049,0.045). After treatment, NLR, NK ratio before and after treatment and PD-L1 were independent factors affecting the immunotherapeutic effect of NSCLC patients(P<0.05). With the increase of NK ratio before and after treatment, the risk of PD response in NSCLC patients increased (nonlinear=0.376,P=0.099). Conclusion: The dynamic changes of NK cells in NSCLC patients before and after anti PD-L1 treatment are significantly correlated with the response to treatment.

参考文献：

[1] LEADER A M,GROUT J A,MAIER B B,et al.Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J].Cancer Cell,2021,39(12):1594-1609.e12.
[2] RECK M,REMON J,HELLMANN M D.First-line immunotherapy for non-small-cell lung cancer[J].J Clin Oncol,2022,40(6):586-597.
[3] ETTINGER D S,WOOD D E,AISNER D L,et al.Non-Small Cell Lung Cancer,Version 3.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(5):497-530.
[4] 国家癌症中心,国家肿瘤质控中心肺癌质控专家委员会.中国原发性肺癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(7):594-599.
[5] FORDE P M,SPICER J,LU S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J].N Engl J Med,2022,386(21):1973-1985.
[6] SUN C,MEZZADRA R,SCHUMACHER T N.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3):434-452.
[7] WU S Y,FU T,JIANG Y Z,et al.Natural killer cells in cancer biology and therapy[J].Mol Cancer,2020,19(1):120.
[8] 中华人民共和国国家卫生健康委员会.原发性肺癌诊疗规范(2018年版)[EB/OL].[2018-12-21].http://www.nhc.gov.cn/yzygj/s7659/201812/b21802b199814ab7b1219b87de0cae51.shtml
[9] 周彩存,王洁,王宝成,等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)[J].中国肺癌杂志,2021,24(4):217-235.
[10] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[11] BODOR J N,BOUMBER Y,BORGHAEI H.Biomarkers for immune checkpoint inhibition in non-small cell lung cancer(NSCLC)[J].Cancer,2020,126(2):260-270.
[12] PENG L,WANG Y,LIU F,et al.Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J].Cancer Immunol Immun,2020,69(9):1813-1822.
[13] NELLI F,PANICHI V,FABBRI A,et al.Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive non-small-cell lung cancer undergoing immune checkpoint inhibitors as second-line therapy[J].Cancer Invest,2022,40(8):710-721.
[14] DINGEMANS A C,HENDRIKS L,BERGHMANS T,et al.Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report[J].J Thorac Oncol,2019,14(12):2109-2119.
[15] HUANG Z,FU Z,HUANG W,et al.Prognostic value of neutrophil-to-lymphocyte ratio in sepsis:a meta-analysis[J].Am J Emerg Med,2020,38(3):641-647.
[16] ZAHOREC R.Neutrophil-to-lymphocyte ratio,past,present and future perspectives[J].Bratisl Lek Listy,2021,122(7):474-488.
[17] 夏经纬,陈羽中,温少迪,等.外周血炎症指标作为预测性指标在晚期非小细胞肺癌免疫治疗中的应用[J].中国肺癌杂志,2021,24(9):632-645.
[18] CHRISTOFORI G.New signals from the invasive front[J].Nature,2006,441(7092):444-450.
[19] SHI J,HOU S,FANG Q,et al.PD-1 controls follicular T helper cell positioning and function[J].Immunity,2018,49(2):264-274.e4.
[20] 顾丽琴,濮阳隆翔,谢芳.PD-1/PD-L1参与NK细胞调控抗肿瘤免疫的作用机制[J].临床与实验病理学杂志,2022,38(4):452-455.
[21] HSU J,HODGINS J J,MARATHE M,et al.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J].J Clin Invest,2018,128(10):4654-4668.
[22] KIM N,KIM H S.Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells[J].Front Immunol,2018,9:2041.
[23] 国家卫生健康委办公厅.原发性肺癌诊疗指南(2022年版)[J].协和医学杂志,2022,13(4):549-570.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录